Derisking Biotech: Smarter Indications and Better Resource Stretching for Early Teams

Derisk you biotech assets with 3 key coniderations. Learn from drug development expert Angelique Greco and medtech-biotech founders and investors with tangible examples that show how real de-risking plays out. 🔍 What You’ll Learn Drug discovery feels like a maze when you're early in your career, especially when you're trying to build a biotech path without wasting years or cash. This episode gives you a clear way to turn solid science into something fundable.You’ll learn: • Where to find real support, from incubators to honest VC advice • Why early commercial input matters and how to fix your market slide • How smart entry points like animal health or adjacent indications de-risk your program and boost your funding chancesAction: Press play if you want 20 minutes that cut months of guesswork.🧠 About the Guest This episode brings insights from ShanShan Wang (RoamTech AI), Anushi Rajapaksa (Misti), Maryam Parviz (SDIP Innovations), Mike Lamprecht (Tenmile), and Ben Wright (Mimetic MedTech Foundry) on how founders can derisk and resource their team. Plus why you do not always need an indication at the start, with lessons from Dr Chris Burns, whose team discovered Momelotinib in Australia before its FDA approval.📌 Episode Highlights 00:00 Why de-risking matters for early biotech founders 00:20 Two angles: advice and smarter indication choices 01:00 How drug discovery fits a STEM entrepreneur path 01:40 Upskilling vs burning cash and time 02:10 Three pillars: compass, investors, venture studiosRoadmap & Upskilling 03:00 The value of a commercialization roadmap 03:45 Han Wang on first seeing the map 04:30 Anushi Rajapaksa on IP, regulatory and evolving the plan 06:00 Where to find training, Bridge program, NSW program 07:00 Why programs matter for network and support 08:00 Maryam Parviz on global doors opening 09:30 What you cannot Google: real conversations 10:30 How informal mentoring happens 11:00 Using tech transfer offices even if you're externalInvestor Advice 12:00 Why VC advice matters before fundraising 13:00 Mike Lamprecht on critical early experiments 14:00 What a realistic market conversation looks likeBridging Your Gaps 15:00 When to stop upskilling and bring experts 15:40 Ben Wright on scaling support instead of solo learning 16:00 How investors view founders who learn on the job 17:00 How venture studios derisk early biotech and medtech 18:00 Why structure and clinical champions matterSuccess Exists 18:45 Momelotinib as a real success story 19:10 When starting with the molecule works 20:00 Dr Chris Burns: from discovery to 2023 approvalSmarter Entry Points 22:00 Why some programs need a side door 22:30 What to check before picking an entry point 23:00 Ivermectin from livestock to humans 24:30 Ketamine and S-ketamine into severe depression 26:00 How new IP opened new paths 26:40 The semaglutide pivotFinal Takeaways 27:00 Do not do it alone 27:15 Get advice early, including from VC 27:30 Philanthropy can be a real path 27:45 Be realistic and optimistic, success existsWant to craft a career story that opens doors?I help STEMM professionals speak with clarity, confidence, and purpose and show up as thought leaders —so the right opportunities find you.📬 Let’s connect: angeliquegreco.com.au | LinkedIn  ⭐️ Help More People Reinvent Their CareersIf you enjoyed this episode, please:✅ Leave a quick ⭐️⭐️⭐️⭐️⭐️ review on Apple Podcasts or Spotify 🙏♻️ Share it with a friend who's questioning their path in STEM Hosted on Acast. See acast.com/privacy for more information.